author-photo

Wendy Wen Xiong

University of Texas MD Anderson Cancer Center

3

Papers

2

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer)

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (2)